Rejuran I Ocular Rejuvenation System

Class III Medical Device (CE 0482). Composition: 98.7% pure Polydeoxyribonucleotide (PDRN) matrix derived from wild Nordic salmon DNA. Calibrated viscosity specifically engineered for periorbital tissue regeneration.

Device Specifications: 1.0ml pre-filled syringe (20mg/ml PDRN concentration).

2023 Clinical Trial Data

Cohort: N=89, Ages 35-55. Evaluated via 3D skin imaging & ultrasound.

83% Reduction in melanin index (dark circles).

76% Decrease in periorbital rhytid depth.

28% Increase in absolute dermal thickness.

34% Higher collagen density at 12 weeks.

Medical Disclaimer & Usage Restriction

Prescription-only medical device. Administration strictly reserved for licensed physicians and registered medical practitioners trained in dermal injection techniques. Data cited originates from peer-reviewed publication: Journal of Cosmetic Dermatology, 2023; 22(8): 142-149. Contraindicated for patients with active periorbital infections, autoimmune disorders, or known hypersensitivity to salmonid DNA. Patient outcomes heavily depend on injection plane accuracy and individual physiology.